dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our quarterly U.S. diabetes survey found one-third of respondents had mild or severe depression, underscoring the need for more support and better treatments.
Erik Shoger presented real-world patient insights at the FDA advisory meeting on sotagliflozin, highlighting the need for education and training if approved.
We invite you to watch this 4-minute selfie video reel featuring real people describing their very real struggles with diabetes.
Our research explores the connection between time-in-range and mental health in people with type 1 and type 2 diabetes.
Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.
Our research found that social stigma perceptions were more common in type 1 diabetes than type 2, possibly because type 2 is less visible.
